The antitumor activity of pembrolizumab was modest in patients with recurrent or newly diagnosed advanced ovarian cancer even if the expression of programmed cell death-Ligand 1 (PD-L1) was high (44–48), suggesting that other tumor immune-evasive mechanisms remain in HGSOC. This evidence concerns the gene CD274 and ovarian cancer.